NEJM Group

CardioExchange Archive

CardioExchange, an NEJM practice community for medical professionals dedicated to improving cardiac patient care, was active from 2009 to 2015. CardioExchange fostered discussion between clinicians from across the globe.

March 9th, 2013

ACC.13 Headquarters

CardioExchange Editors, Staff

CardioExchange is dedicated to bringing you the latest from ACC.13. Check out our coverage below ─ and some of the great debates these posts have sparked ─ then tell us what you think!

News:

  • Following an Embargo Break PREVAIL Trial Won’t be Presented at ACC
  • HPS2-THRIVE: A ‘Disappointing But Clear’ Result
  • Cangrelor During PCI May Reduce Ischemic Events
  • Fibrinolysis May Benefit Late-Arriving STEMI Patients
  • Eplerenone May Prevent Heart Failure in Acute STEMI Patients
  • Another Negative Trial of Darbepoetin Alfa
  • Was Atherosclerosis the Real Curse of the Mummy?
  • Two Trials Explore On-Pump Versus Off-Pump Bypass Surgery

Analysis:

  • Is Cangrelor an Antiplatelet CHAMPION?

Follow our Fellows:

  • The Real World Intrudes on the Start of the Meeting
  • A Fellow Reflects on the Program and on her Progress from Observer to Educator
  • Data Sources for Young Investigators
  • New Approaches to LDL Lowering
  • Great Venue, Great Sessions, but Disappointments Too
  • Thinking About What Comes After Fellowship
  • The Real Question About Reducing Hospital Readmissions
  • You Are My Sunshine
  • Learning to Network

Categories: General
Tags: ACC.13


You can follow any responses to this entry through the RSS 2.0 feed. Both comments and pings are currently closed.

Comments are closed.

  • Search the Archive

  • Archives by Date

  • RSS NEJM — Recent Cardiology Articles

    • Complete Revascularization Guided by Functional Coronary Angiography in STEMI September 10, 2026
      Among patients with ST-segment elevation myocardial infarction and multivessel disease, physiology-guided angiography led to a lower risk of major cardiovascular events than conventional angiography-guided treatment.
    • Oveporexton for Narcolepsy Type 1 — Results from Two Phase 3 Trials September 9, 2026
      In two placebo-controlled trials, oveporexton improved wakefulness, reduced daytime sleepiness, and lowered the cataplexy rate among patients with narcolepsy type 1. Increased urinary frequency and transient insomnia were common.
    • Immediate Ambulatory Electrocardiographic Monitoring in Syncope August 31, 2026
      Among patients with syncope that remained unexplained after evaluation in the ED, immediate initiation of 14-day ECG monitoring did not result in significantly fewer patient-reported syncope episodes at 1 year than standard care.
    • Catheter-Directed Thrombolysis in Intermediate-High–Risk Pulmonary Embolism August 31, 2026
      Catheter-directed thrombolysis led to a lower risk of death, recurrent pulmonary embolism, or cardiorespiratory decompensation or collapse at 7 days than anticoagulation alone in intermediate-high–risk acute pulmonary embolism.
    • Timing of PCI in Patients Undergoing Transcatheter Aortic-Valve Implantation August 30, 2026
      In patients with severe aortic stenosis and coronary artery disease, a strategy of transcatheter aortic-valve implantation before percutaneous coronary intervention was noninferior to PCI before TAVI for major clinical events at 1 year.
  • Tag Cloud

    • ACS AF AHA anticoagulation aortic valve replacement apixaban aspirin atrial fibrillation CABG cardiovascular risk cholesterol clopidogrel dabigatran diabetes diet drug-eluting stents epidemiology ESC exercise FDA FDA approvals Fellowship training guidelines HDL heart failure hypertension ICDs MI myocardial infarction obesity PCI Primary PCI risk factors rivaroxaban statins STEMI stents stroke stroke prevention TAVI TAVR type 2 diabetes venous thromboembolism warfarin women
NEJM Group

Copyright © 2026 Massachusetts Medical Society. All rights reserved.

The content of this site is intended for health care professionals. Copyright | Terms | Privacy Policy |